Bretisilocin

Common card · No. 447980

Bretisilocin, also known by its developmental code name GM-2505 and as 5-fluoro-N-methyl-N-ethyltryptamine (5F-MET or 5-fluoro-MET), is a serotonergic psychedelic of the tryptamine family which is under development for the treatment of major depressive disorder. It is an analogue of dimethyltryptamine (DMT) and is the 5-fluorinated derivative of methylethyltryptamine (MET). Bretisilocin's route of administration is intravenous infusion. The drug acts as a potent and well-balanced serotonin 5-HT2A and 5-HT2C receptor agonist, serotonin 5-HT2B receptor partial agonist or antagonist, and serotonin releasing agent. It produces psychedelic-like effects in animals and similarly produces robust hallucinogenic effects in humans. The duration of bretisilocin is 60 to 90 minutes and is intermediate between the durations of DMT and psilocybin. It has been regarded by its developer as an "improved version of DMT". Bretisilocin was patented by Andrew Kruegel and Gilgamesh Pharmaceuticals in 2021. It...

Read on Wikipedia · Image Alliegaytor, Public domain